Insights into the L,D-Transpeptidases and D,D-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors
Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins (M. abscessus L,D-transpeptidases 1 to 5 [Ldt(Mab1) to Ldt(Mab5)] and D,D-carboxypeptid...
Gespeichert in:
| Veröffentlicht in: | Antimicrobial agents and chemotherapy 2020-07, Vol.64 (8), Article 00098 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | |
| container_title | Antimicrobial agents and chemotherapy |
| container_volume | 64 |
| creator | Dousa, Khalid M. Kurz, Sebastian G. Taracila, Magdalena A. Bonfield, Tracey Bethel, Christopher R. Barnes, Melissa D. Selvaraju, Suresh Abdelhamed, Ayman M. Kreiswirth, Barry N. Boom, W. Henry Kasperbauer, Shannon H. Daley, Charles L. Bonomo, Robert A. |
| description | Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins (M. abscessus L,D-transpeptidases 1 to 5 [Ldt(Mab1) to Ldt(Mab5)] and D,D-carboxypeptidase) that are targeted by beta-lactam antibiotics. A challenge to this approach is the presence of chromosomally encoded beta-lactamase (Bla(Mab)). Using a mechanism-based approach, we found that a novel ceftaroline-imipenem combination effectively lowered the MICs of M. abscessus isolates (MIC50 = 8 angstrom for ceftaroline to enter. Our analysis demonstrates that ceftaroline and imipenem binding to multiple targets (L,D-transpeptidases and D,D-carboxypeptidase) and provides a mechanistic rationale for the effectiveness of this dual beta-lactam combination in M. abscessus infections. |
| doi_str_mv | 10.1128/AAC.00098-20 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_asm2_</sourceid><recordid>TN_cdi_asm2_journals_10_1128_AAC_00098_20</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2401815198</sourcerecordid><originalsourceid>FETCH-LOGICAL-a488t-b0f82fd9ca582d9cce9302702cafccde4adbe83d3dc4e65ae1f17702762c8c9b3</originalsourceid><addsrcrecordid>eNqNkc2O0zAUhSMEYjoDO9bIS9A0g-38OSyQqpSfSgU2w9q6cW6mHiV2sZ2B8ia8LW47VLBAYmXL59Nn3XuS5BmjV4xx8WqxaK4opbVIOX2QzNj-VhZ1-TCZUVqWaS5ofpace38bqRjQx8lZxrM6y-t6lvxcGa9vNsETbYIlYYNkPV-m1w6M3-I26A48egKmI8v43oBr7ffdKSG2Jx93yragAjo9jQRar9D7yb8mDfYBnB20wTlZjXqLBsf5wfXJ3uFAlhp-QKvVTg3WqgAGycpsdKuDdf5J8qiHwePT-_Mi-fLu7XXzIV1_fr9qFusUciFC2tJe8L6rFRSCx0NhnVFeUa6gV6rDHLoWRdZlncqxLABZz6oYVyVXQtVtdpG8OXq3Uztip9AEB4PcOj2C20kLWv6dGL2RN_ZOVgUvRU6j4MW9wNmvE_ogRx13MAxxHjt5yXPKBCtYLSI6P6LKWe8d9qdvGJX7NmVsUx7alHxvfnnEwY9c3trJmbiJf7HP_xzjJP5ddQQuj8A3bG3vlUaj8IRFT1Fl9X41lB504v_pRgcI2prGTiZkvwDytMyE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2401815198</pqid></control><display><type>article</type><title>Insights into the L,D-Transpeptidases and D,D-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Dousa, Khalid M. ; Kurz, Sebastian G. ; Taracila, Magdalena A. ; Bonfield, Tracey ; Bethel, Christopher R. ; Barnes, Melissa D. ; Selvaraju, Suresh ; Abdelhamed, Ayman M. ; Kreiswirth, Barry N. ; Boom, W. Henry ; Kasperbauer, Shannon H. ; Daley, Charles L. ; Bonomo, Robert A.</creator><creatorcontrib>Dousa, Khalid M. ; Kurz, Sebastian G. ; Taracila, Magdalena A. ; Bonfield, Tracey ; Bethel, Christopher R. ; Barnes, Melissa D. ; Selvaraju, Suresh ; Abdelhamed, Ayman M. ; Kreiswirth, Barry N. ; Boom, W. Henry ; Kasperbauer, Shannon H. ; Daley, Charles L. ; Bonomo, Robert A.</creatorcontrib><description>Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins (M. abscessus L,D-transpeptidases 1 to 5 [Ldt(Mab1) to Ldt(Mab5)] and D,D-carboxypeptidase) that are targeted by beta-lactam antibiotics. A challenge to this approach is the presence of chromosomally encoded beta-lactamase (Bla(Mab)). Using a mechanism-based approach, we found that a novel ceftaroline-imipenem combination effectively lowered the MICs of M. abscessus isolates (MIC50 <= 0.25 mu g/ml; MIC90 <= 0.5 mu g/ml). Combining ceftaroline and imipenem with a beta-lactamase inhibitor, i.e., relebactam or avibactam, demonstrated only a modest effect on susceptibility compared to each of the beta-lactams alone. In steady-state kinetic assays, Bla(Mab) exhibited a lower K-i app (0.30 +/- 0.03 mu M for avibactam and 136 +/- 14 mu M for relebactam) and a higher acylation rate for avibactam (k(2)/K= 3.4 x 10(5) +/- 0.4 x 10(5) M-1 s(-1) for avibactam and 6 x 10(2) +/- 0.6 x 10(2) M-1 s(-1) for relebactam). The k(cat)/K-m was nearly 10-fold lower for ceftaroline fosamil (0.007 +/- 0.001 mu M-1 s(-1)) than for imipenem (0.056 +/- 0.006 mu M-1 s(-1)). Timed mass spectrometry captured complexes of avibactam and Bla(Mab), Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), and D,D-carboxypeptidase, whereas relebactam bound only Bla(Mab), Ldt(Mab1), and Ldt(Mab2). Interestingly, Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), Ldt(Mab5), and D,D-carboxypeptidase bound only to imipenem when incubated with imipenem and ceftaroline fosamil. We next determined the binding constants of imipenem and ceftaroline fosamil for Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), and Ldt(Mab5) and showed that imipenem bound >100-fold more avidly than ceftaroline fosamil to Ldt(Mab1), and Ldt(Mab2) (e.g., K-i (app) or K-m of Ldt(Mab1), = 0.01 +/- 0.01 mu M for imipenem versus 0.73 +/- 0.08 mu M for ceftaroline fosamil). Molecular modeling indicates that Ldt(Mab2) readily accommodates imipenem, but the active site must widen to >= 8 angstrom for ceftaroline to enter. Our analysis demonstrates that ceftaroline and imipenem binding to multiple targets (L,D-transpeptidases and D,D-carboxypeptidase) and provides a mechanistic rationale for the effectiveness of this dual beta-lactam combination in M. abscessus infections.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.00098-20</identifier><identifier>PMID: 32393499</identifier><language>eng</language><publisher>WASHINGTON: Amer Soc Microbiology</publisher><subject>Anti-Bacterial Agents - pharmacology ; Azabicyclo Compounds - pharmacology ; beta-Lactamase Inhibitors ; Carboxypeptidases ; Ceftaroline ; Cephalosporins ; Imipenem - pharmacology ; Life Sciences & Biomedicine ; Mechanisms of Resistance ; Microbial Sensitivity Tests ; Microbiology ; Mycobacterium abscessus ; Peptidyl Transferases ; Pharmacology & Pharmacy ; Science & Technology</subject><ispartof>Antimicrobial agents and chemotherapy, 2020-07, Vol.64 (8), Article 00098</ispartof><rights>This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>32</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000573917700020</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-a488t-b0f82fd9ca582d9cce9302702cafccde4adbe83d3dc4e65ae1f17702762c8c9b3</citedby><cites>FETCH-LOGICAL-a488t-b0f82fd9ca582d9cce9302702cafccde4adbe83d3dc4e65ae1f17702762c8c9b3</cites><orcidid>0000-0003-3272-7231</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526840/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526840/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,28255,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32393499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dousa, Khalid M.</creatorcontrib><creatorcontrib>Kurz, Sebastian G.</creatorcontrib><creatorcontrib>Taracila, Magdalena A.</creatorcontrib><creatorcontrib>Bonfield, Tracey</creatorcontrib><creatorcontrib>Bethel, Christopher R.</creatorcontrib><creatorcontrib>Barnes, Melissa D.</creatorcontrib><creatorcontrib>Selvaraju, Suresh</creatorcontrib><creatorcontrib>Abdelhamed, Ayman M.</creatorcontrib><creatorcontrib>Kreiswirth, Barry N.</creatorcontrib><creatorcontrib>Boom, W. Henry</creatorcontrib><creatorcontrib>Kasperbauer, Shannon H.</creatorcontrib><creatorcontrib>Daley, Charles L.</creatorcontrib><creatorcontrib>Bonomo, Robert A.</creatorcontrib><title>Insights into the L,D-Transpeptidases and D,D-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors</title><title>Antimicrobial agents and chemotherapy</title><addtitle>ANTIMICROB AGENTS CH</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins (M. abscessus L,D-transpeptidases 1 to 5 [Ldt(Mab1) to Ldt(Mab5)] and D,D-carboxypeptidase) that are targeted by beta-lactam antibiotics. A challenge to this approach is the presence of chromosomally encoded beta-lactamase (Bla(Mab)). Using a mechanism-based approach, we found that a novel ceftaroline-imipenem combination effectively lowered the MICs of M. abscessus isolates (MIC50 <= 0.25 mu g/ml; MIC90 <= 0.5 mu g/ml). Combining ceftaroline and imipenem with a beta-lactamase inhibitor, i.e., relebactam or avibactam, demonstrated only a modest effect on susceptibility compared to each of the beta-lactams alone. In steady-state kinetic assays, Bla(Mab) exhibited a lower K-i app (0.30 +/- 0.03 mu M for avibactam and 136 +/- 14 mu M for relebactam) and a higher acylation rate for avibactam (k(2)/K= 3.4 x 10(5) +/- 0.4 x 10(5) M-1 s(-1) for avibactam and 6 x 10(2) +/- 0.6 x 10(2) M-1 s(-1) for relebactam). The k(cat)/K-m was nearly 10-fold lower for ceftaroline fosamil (0.007 +/- 0.001 mu M-1 s(-1)) than for imipenem (0.056 +/- 0.006 mu M-1 s(-1)). Timed mass spectrometry captured complexes of avibactam and Bla(Mab), Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), and D,D-carboxypeptidase, whereas relebactam bound only Bla(Mab), Ldt(Mab1), and Ldt(Mab2). Interestingly, Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), Ldt(Mab5), and D,D-carboxypeptidase bound only to imipenem when incubated with imipenem and ceftaroline fosamil. We next determined the binding constants of imipenem and ceftaroline fosamil for Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), and Ldt(Mab5) and showed that imipenem bound >100-fold more avidly than ceftaroline fosamil to Ldt(Mab1), and Ldt(Mab2) (e.g., K-i (app) or K-m of Ldt(Mab1), = 0.01 +/- 0.01 mu M for imipenem versus 0.73 +/- 0.08 mu M for ceftaroline fosamil). Molecular modeling indicates that Ldt(Mab2) readily accommodates imipenem, but the active site must widen to >= 8 angstrom for ceftaroline to enter. Our analysis demonstrates that ceftaroline and imipenem binding to multiple targets (L,D-transpeptidases and D,D-carboxypeptidase) and provides a mechanistic rationale for the effectiveness of this dual beta-lactam combination in M. abscessus infections.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Azabicyclo Compounds - pharmacology</subject><subject>beta-Lactamase Inhibitors</subject><subject>Carboxypeptidases</subject><subject>Ceftaroline</subject><subject>Cephalosporins</subject><subject>Imipenem - pharmacology</subject><subject>Life Sciences & Biomedicine</subject><subject>Mechanisms of Resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbiology</subject><subject>Mycobacterium abscessus</subject><subject>Peptidyl Transferases</subject><subject>Pharmacology & Pharmacy</subject><subject>Science & Technology</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkc2O0zAUhSMEYjoDO9bIS9A0g-38OSyQqpSfSgU2w9q6cW6mHiV2sZ2B8ia8LW47VLBAYmXL59Nn3XuS5BmjV4xx8WqxaK4opbVIOX2QzNj-VhZ1-TCZUVqWaS5ofpace38bqRjQx8lZxrM6y-t6lvxcGa9vNsETbYIlYYNkPV-m1w6M3-I26A48egKmI8v43oBr7ffdKSG2Jx93yragAjo9jQRar9D7yb8mDfYBnB20wTlZjXqLBsf5wfXJ3uFAlhp-QKvVTg3WqgAGycpsdKuDdf5J8qiHwePT-_Mi-fLu7XXzIV1_fr9qFusUciFC2tJe8L6rFRSCx0NhnVFeUa6gV6rDHLoWRdZlncqxLABZz6oYVyVXQtVtdpG8OXq3Uztip9AEB4PcOj2C20kLWv6dGL2RN_ZOVgUvRU6j4MW9wNmvE_ogRx13MAxxHjt5yXPKBCtYLSI6P6LKWe8d9qdvGJX7NmVsUx7alHxvfnnEwY9c3trJmbiJf7HP_xzjJP5ddQQuj8A3bG3vlUaj8IRFT1Fl9X41lB504v_pRgcI2prGTiZkvwDytMyE</recordid><startdate>20200722</startdate><enddate>20200722</enddate><creator>Dousa, Khalid M.</creator><creator>Kurz, Sebastian G.</creator><creator>Taracila, Magdalena A.</creator><creator>Bonfield, Tracey</creator><creator>Bethel, Christopher R.</creator><creator>Barnes, Melissa D.</creator><creator>Selvaraju, Suresh</creator><creator>Abdelhamed, Ayman M.</creator><creator>Kreiswirth, Barry N.</creator><creator>Boom, W. Henry</creator><creator>Kasperbauer, Shannon H.</creator><creator>Daley, Charles L.</creator><creator>Bonomo, Robert A.</creator><general>Amer Soc Microbiology</general><general>American Society for Microbiology</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3272-7231</orcidid></search><sort><creationdate>20200722</creationdate><title>Insights into the L,D-Transpeptidases and D,D-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors</title><author>Dousa, Khalid M. ; Kurz, Sebastian G. ; Taracila, Magdalena A. ; Bonfield, Tracey ; Bethel, Christopher R. ; Barnes, Melissa D. ; Selvaraju, Suresh ; Abdelhamed, Ayman M. ; Kreiswirth, Barry N. ; Boom, W. Henry ; Kasperbauer, Shannon H. ; Daley, Charles L. ; Bonomo, Robert A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a488t-b0f82fd9ca582d9cce9302702cafccde4adbe83d3dc4e65ae1f17702762c8c9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Azabicyclo Compounds - pharmacology</topic><topic>beta-Lactamase Inhibitors</topic><topic>Carboxypeptidases</topic><topic>Ceftaroline</topic><topic>Cephalosporins</topic><topic>Imipenem - pharmacology</topic><topic>Life Sciences & Biomedicine</topic><topic>Mechanisms of Resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbiology</topic><topic>Mycobacterium abscessus</topic><topic>Peptidyl Transferases</topic><topic>Pharmacology & Pharmacy</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dousa, Khalid M.</creatorcontrib><creatorcontrib>Kurz, Sebastian G.</creatorcontrib><creatorcontrib>Taracila, Magdalena A.</creatorcontrib><creatorcontrib>Bonfield, Tracey</creatorcontrib><creatorcontrib>Bethel, Christopher R.</creatorcontrib><creatorcontrib>Barnes, Melissa D.</creatorcontrib><creatorcontrib>Selvaraju, Suresh</creatorcontrib><creatorcontrib>Abdelhamed, Ayman M.</creatorcontrib><creatorcontrib>Kreiswirth, Barry N.</creatorcontrib><creatorcontrib>Boom, W. Henry</creatorcontrib><creatorcontrib>Kasperbauer, Shannon H.</creatorcontrib><creatorcontrib>Daley, Charles L.</creatorcontrib><creatorcontrib>Bonomo, Robert A.</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dousa, Khalid M.</au><au>Kurz, Sebastian G.</au><au>Taracila, Magdalena A.</au><au>Bonfield, Tracey</au><au>Bethel, Christopher R.</au><au>Barnes, Melissa D.</au><au>Selvaraju, Suresh</au><au>Abdelhamed, Ayman M.</au><au>Kreiswirth, Barry N.</au><au>Boom, W. Henry</au><au>Kasperbauer, Shannon H.</au><au>Daley, Charles L.</au><au>Bonomo, Robert A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into the L,D-Transpeptidases and D,D-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>ANTIMICROB AGENTS CH</stitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2020-07-22</date><risdate>2020</risdate><volume>64</volume><issue>8</issue><artnum>00098</artnum><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins (M. abscessus L,D-transpeptidases 1 to 5 [Ldt(Mab1) to Ldt(Mab5)] and D,D-carboxypeptidase) that are targeted by beta-lactam antibiotics. A challenge to this approach is the presence of chromosomally encoded beta-lactamase (Bla(Mab)). Using a mechanism-based approach, we found that a novel ceftaroline-imipenem combination effectively lowered the MICs of M. abscessus isolates (MIC50 <= 0.25 mu g/ml; MIC90 <= 0.5 mu g/ml). Combining ceftaroline and imipenem with a beta-lactamase inhibitor, i.e., relebactam or avibactam, demonstrated only a modest effect on susceptibility compared to each of the beta-lactams alone. In steady-state kinetic assays, Bla(Mab) exhibited a lower K-i app (0.30 +/- 0.03 mu M for avibactam and 136 +/- 14 mu M for relebactam) and a higher acylation rate for avibactam (k(2)/K= 3.4 x 10(5) +/- 0.4 x 10(5) M-1 s(-1) for avibactam and 6 x 10(2) +/- 0.6 x 10(2) M-1 s(-1) for relebactam). The k(cat)/K-m was nearly 10-fold lower for ceftaroline fosamil (0.007 +/- 0.001 mu M-1 s(-1)) than for imipenem (0.056 +/- 0.006 mu M-1 s(-1)). Timed mass spectrometry captured complexes of avibactam and Bla(Mab), Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), and D,D-carboxypeptidase, whereas relebactam bound only Bla(Mab), Ldt(Mab1), and Ldt(Mab2). Interestingly, Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), Ldt(Mab5), and D,D-carboxypeptidase bound only to imipenem when incubated with imipenem and ceftaroline fosamil. We next determined the binding constants of imipenem and ceftaroline fosamil for Ldt(Mab1), Ldt(Mab2), Ldt(Mab4), and Ldt(Mab5) and showed that imipenem bound >100-fold more avidly than ceftaroline fosamil to Ldt(Mab1), and Ldt(Mab2) (e.g., K-i (app) or K-m of Ldt(Mab1), = 0.01 +/- 0.01 mu M for imipenem versus 0.73 +/- 0.08 mu M for ceftaroline fosamil). Molecular modeling indicates that Ldt(Mab2) readily accommodates imipenem, but the active site must widen to >= 8 angstrom for ceftaroline to enter. Our analysis demonstrates that ceftaroline and imipenem binding to multiple targets (L,D-transpeptidases and D,D-carboxypeptidase) and provides a mechanistic rationale for the effectiveness of this dual beta-lactam combination in M. abscessus infections.</abstract><cop>WASHINGTON</cop><pub>Amer Soc Microbiology</pub><pmid>32393499</pmid><doi>10.1128/AAC.00098-20</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-3272-7231</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4804 |
| ispartof | Antimicrobial agents and chemotherapy, 2020-07, Vol.64 (8), Article 00098 |
| issn | 0066-4804 1098-6596 |
| language | eng |
| recordid | cdi_asm2_journals_10_1128_AAC_00098_20 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
| subjects | Anti-Bacterial Agents - pharmacology Azabicyclo Compounds - pharmacology beta-Lactamase Inhibitors Carboxypeptidases Ceftaroline Cephalosporins Imipenem - pharmacology Life Sciences & Biomedicine Mechanisms of Resistance Microbial Sensitivity Tests Microbiology Mycobacterium abscessus Peptidyl Transferases Pharmacology & Pharmacy Science & Technology |
| title | Insights into the L,D-Transpeptidases and D,D-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-08T05%3A18%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_asm2_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20the%20L,D-Transpeptidases%20and%20D,D-Carboxypeptidase%20of%20Mycobacterium%20abscessus:%20Ceftaroline,%20Imipenem,%20and%20Novel%20Diazabicyclooctane%20Inhibitors&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Dousa,%20Khalid%20M.&rft.date=2020-07-22&rft.volume=64&rft.issue=8&rft.artnum=00098&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.00098-20&rft_dat=%3Cproquest_asm2_%3E2401815198%3C/proquest_asm2_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2401815198&rft_id=info:pmid/32393499&rfr_iscdi=true |